Abstract: Recent technological advances in NMR methods and instrumentation are having a significant impact in structural biology. These innovations are also impacting pharmaceutical biotechnology as it is now possible to use NMR spectroscopy to rapidly characterize a growing number of prospective protein drugs and protein drug targets. This review provides a general summary of how solution-state NMR can be used to determine protein structures. It also focuses on exploring how advances in solution state NMR are changing the way in which protein structures can be determined and protein-ligand interactions can be characterized. Recent innovations in protein sample preparation, in instrumentation and data collection, in spectral assignment and in structure generation are highlighted. The impact of solution-state NMR on pharmaceutical biotechnology is also discussed, with a special emphasis on describing how NMR has been used to study a number of pharmaceutically important proteins and how NMR is currently being used to rapidly screen and to map the binding sites of small molecules to a range of protein targets.
INTRODUCTION
Over the past 20 years, advances in structural biology have profoundly changed the way in which drugs are designed and discovered. Today, rather than treating protein targets as simple black boxes, pharmaceutical scientists are now treating them as complex molecular entities that possess well-defined structures with active sites that can be rationally activated or deactivated with small molecule ligands. Innovations in structure determination methods along with rapid advances in molecular visualization tools have led to the emergence of structure-aided drug design or rational drug design as an integral part of the drug discovery and development process [1, 2] . Of course, the rational design of any drug depends on a precise knowledge of the 3D structure of the protein target. To date, the most prominent technique for 3D structure determination has been X-ray crystallography [3] . No other method of structure determination can match X-ray crystallography's capacity for generating the structures of important proteins or protein complexes such as polymerases, proteosomes, viruses, and ribosomes. However, not all proteins are conducive to crystallization and not all proteins behave or look the same in a crystalline state as they do in the cellular milieu [4] . In this regard, nuclear magnetic resonance (NMR) spectroscopy has emerged as an important alternative to X-ray crystallography as it allows protein structures to be determined in conditions that are very close to the physiological state (i.e. in solution). What's more, NMR spectroscopy provides structural biologists the opportunity to measure events or processes that cannot readily be seen or quantified by X-ray crystallography, such as protein kinetics, dynamics or thermodynamics [4] [5] [6] . This review is concerned with describing how solutionstate NMR spectroscopy can be used to determine the structures of peptides, proteins and protein-ligand complexes of pharmaceutical interest. In addition to providing a basic overview of protein NMR methods, this article will also describe some of the emerging or more innovative methods that are making NMR spectroscopy and NMR-based structure determination much faster and much more robust. Examples will also be provided to illustrate how NMR can be used to screen protein targets with drug libraries, characterize weakly binding protein-ligand complexes and derive useful dynamic or thermodynamic information. The primary intent of this review is to provide a basic introduction to solution-state protein NMR and to illustrate how protein NMR can and should be a vital part of drug discovery and development.
NMR BASICS
NMR spectroscopy is a spectroscopic technique which measures the absorbance of radio frequency (RF) radiation that occurs when certain kinds of atomic nuclei ( 1 H, 13 C, 15 N) are placed under strong magnetic fields. The positions of the absorption frequencies or "resonances" that can be detected are called chemical shifts. Chemical shifts are very sensitive to the electronic environment surrounding each nucleus and can provide a great deal of information about a molecule's covalent and non-covalent structure [7, 8] . Many NMR resonances also display a fine structure characterized by split peaks (doublets or triplets) arising from magnetic coupling between adjacent, or covalently bonded nuclei. This peaksplitting phenomenon is called spin-spin or J coupling and it too can be used to infer knowledge about a molecule's covalent geometry [8] . Additionally, nuclei can also transfer energy or magnetization to each other, both through bonds and through space (for short distances). This transfer process is called the nuclear Overhauser effect or NOE [9] . The intensity of a NOE resonance is inversely proportional to the sixth power of the distance between nuclei. This distance dependence means the NOE phenomenon is frequently exploited to determine molecular geometry [10] .
Relative to most other kinds of spectroscopy, NMR is unique in the degree of resolution (sharpness of peaks) that it offers. The narrow peaks in NMR are actually a consequence of the rapid molecular tumbling that happens in solution. This random tumbling slows the magnetic relaxation times (T 1 and T 2 ) and sharpens the energy transitions. This exceptional spectral resolution makes NMR much better than UV, fluorescence or IR spectroscopy for extracting detailed atomic or molecular information from chemical compounds. Furthermore, the behavior of nuclei under all kinds of RF excitation conditions is remarkable predictable making NMR very amenable to specially designed experiments which allow magnetization to be manipulated and transferred around a molecular almost at will. These "pulse sequence" experiments or RF manipulations lie at the heart of modern NMR spectroscopy [11] .
Using information about characteristic chemical shifts, known J-couplings, measured line widths and observed NOE's it is possible to determine a great deal about the covalent structure of small molecules. Indeed, NMR has been used as the primary method to determine or confirm organic chemical structures for more than 40 years [12, 13] . Because proteins are essentially polymers of small molecules, many of the same NMR principles used in small molecule chemistry can be applied to proteins. However, proteins possess many more nuclei and display considerably more resonances than small organic molecules. This makes their NMR spectra very difficult to interpret. In fact, it wasn't until the development of 2D NMR spectroscopy in the 1970's that protein NMR could be tackled in earnest [14, 15] . In 2D spectroscopy, NMR resonances are separated not on a single frequency axis but on two frequency (or chemical shift) axes. 2D spectroscopy is the conceptual equivalent of 2D gel electrophoresis, where protein spots are first separated electrophoretically according to their isoelectric point and then according to their mass. 2D separation allows hidden spots to emerge and far more peaks to be positively identified. As we will see shortly, 2D NMR spectroscopy can be easily extended to three dimensions or even four dimensions [16, 17] . In the case of 3D NMR, the peaks are not displayed in a plane, but in a cube (Fig. 1) .
The first NMR protein (peptide) structure was determined in 1981 using protocols and techniques largely developed by Kurt Wuthrich and co-workers [18] . This work was recognized in 2002 when he was awarded the Nobel Prize in chemistry. These early structures were very crude (equivalent resolution to a 3.5 Å X-ray structure) and were limited to very small (<70 residues), well behaved proteins [14] . In the early days, protein structures took months or even years to generate. Since then, enormous strides in both the technology and the technique have been made. Increased magnet field strength of up to 900 MHz [19] , improved probe sensitivity using super-cooled cryogenic probes [20] , more sophisticated hardware [21] , faster computers, better isotopic labeling schemes [22] , higher yielding expression systems [23] , newly measurable spectral parameters [24, 25] , and greatly improved pulse sequences [25, 26] are now allowing larger proteins to be characterized much more quickly and with far greater precision. Proteins as large as 723 residues have been fully assigned [27] and protein complexes as large as 900, 000 daltons have been analyzed [28] . To date, NMR spectroscopy has been used to solve more than 3000 peptide and protein structures, many of which are available from the Protein Data Bank [3] . NMR has clearly come into its own as a structure determination technique. It has also evolved into a vital tool that can reveal much about the interactions, motions, kinetics and thermo-dynamics of proteins and their ligands. Fig. (1) . An illustration of how 1D, 2D and 3D NMR spectra can be viewed. The size or molecular weight limit, in terms of the resolvable peaks that can be detected for each method, is indicated at the bottom of this figure
PROTEIN STRUCTURE BY NMR -A SYNOPSIS
Protein NMR demands a broad range of skills, from molecular biology and protein purification to quantum chemistry and computer programming. Each of these skills is used at different times, with varying degrees of intensity. Fortunately, the process is becoming progressively easier as many aspects of protein NMR are becoming more automated or "recipe" oriented [4, 25, 29] . As a general rule, protein structure determination via NMR can be divided into four steps: 1) sample preparation; 2) data collection; 3) sequential assignment and spectral validation; and finally 4) structure generation and validation. We will discuss each of these steps and some of their more recent innovations in more detail, but before doing so, it is perhaps worthwhile to provide a brief overview of the entire process so that later discussions will be more meaningful.
Protein samples may be either unlabeled ( 1 H only) or labeled with certain NMR sensitive isotopes (i.e. 13 C and 15 N). Because 1 H (we'll use the term proton from here on) is a naturally occurring and highly sensitive NMR nucleus, many smaller peptides and proteins need not be isotopically labeled. In fact, for the first 10 years of protein NMR, most proteins were not labeled [14] . It has only been with the advent of better NMR hardware and NMR pulse sequences that the trend towards isotopically labeled samples has taken off [4, 25, 26] . For larger proteins (>10 kD) or in the pursuit of higher quality structures, most NMR spectroscopists like to work with isotopically labeled proteins. These are prepared by growing cells and expressing the protein in defined minimal media that has been enriched with 13 C and/or 15 N labeled substrates. Once a protein sample is ready for NMR (labeled or unlabeled) and suitable solution conditions found, it is then subject to a series of 2D or 3D NMR experiments. The intent of these experiments is to collect sufficient spectral data so that every NMR peak (or resonance) can be assigned to every NMR detectable atom (or nucleus) in the protein [5, 14] . This process is called sequential assignment. For unlabeled peptides and proteins, the assignment process is relatively straightforward. Two types of 2D NMR experiments are collected. A TOCSY (total correlation spectroscopy) experiment is first collected which allows individual amino acids to be identified by the distinct patterns of their chemical shifts [30] . A NOESY (nuclear Overhauser enhancement spectroscopy) experiment is then collected which yields a spectrum that looks almost identical to the TOCSY spectrum [31] . However, in the NOESY experiment there are extra peaks (often 100's, even 1000's). These extra "pseudo" peaks or cross peaks, which show up between pairs of TOCSY peaks, correspond to interactions where nearby protons are within 5 Å of each other. The stronger the cross peak, the closer the two protons (or amino acids) are. Using NOESY data, in combination with the TOCSY data, it is possible to determine which amino acids are sequentially proximal to each other [32] . In this way each set of peaks in the TOCSY spectrum can be assigned an atom name and a residue number. Once all the TOCSY peaks have been assigned an atom name and a residue number, the sequential assignment process is complete. Note that because only one type of nucleus ( 1 H) is being analyzed, this method is called homonuclear NMR.
When working with isotopically labeled proteins (usually 13 C/ 15 N or double-labeled), the sequential assignment process does not depend on NOESY data at all. Rather, it is possible to use a series of J-coupled 3D NMR experiments to identify individual amino acid types and to identify which pairs of amino acids are sequentially proximal to each other. These 3D NMR experiments are named for the types of nuclei they measure. Hence an HNCA experiment [33] measures the 1 H amide shift of a residue on one axis ("H"), the 15 N amide shift on another axis ("N") and the 13 Cα shift on the third axis ("CA"). See Fig. (2) for an illustration of some common 3D heteronuclar NMR experiments. For example, if we perform an experiment called the HNCACB [34] it is possible to look for very well-defined patterns to determine the amide 1 H shift, the amide 15 N shift, the 13 Cα shift and the 13 Cβ shift for each amino acid residue in the protein. The HNCACB spectrum also yields the 13 Cα and 13 Cβ shifts for the preceding residue (Fig. 2) . Collecting data from another type of experiment called an HCCH-TOCSY [35] it is possible to obtain chemical shifts for the 13 Cα as well as the side chain 13 [17, 29] . This process is called heteronuclear NMR as several different types of nuclei ( 1 H, 13 C, 15 N) are used in the assignment process.
Once the sequential assignment process is completed, it is possible to begin the structure determination process. This is outlined in Fig. (3) . Both the homonuclear and heteronuclear approaches depend on collecting multiple NOESY spectra. By using the sequential assignments already obtained, NOESY cross peaks are identified and quantified. Usually several NOESY spectra are collected with different parameters (mixing times) to determine more precisely the strength of the NOE interaction and to better calibrate the distances between each NOE-active pair of protons. The intensity of each NOE peak is converted to an approximate pairwise separation (1.8-2.8, 1.8-4.0, 1.8-5.0 Å) between as many hydrogen atoms as one can measure [10, 14] . Additional information about secondary structure (derived from chemical shifts - [36, 37] ), coupling constants [38] , hydrogen bonding, and disulfide bonds is also added to a long list of approximate constraints [10] . Typically for a protein of 100 residues one would like to obtain 1500 to 2000 constraints (15-20 constraints per residue). The experimentally derived constraint file is supplemented with covalent geometry constraints about each of the amino acids (bond lengths, bond angles, amino acid planarity and chirality information) known from previous small molecule studies. The combined constraint file is then submitted to a distance geometry program [39] or simulated annealing program for structure generation [40] . These very sophisticated geometry optimization programs attempt to generate a protein structure or set of protein structures that are consistent with the experimental constraints. What normally results from these calculations is a set of possible protein structures (25 to 50), which must be individually evaluated for their fitness and agreement to the experimental data (Fig.  4) . Typically multiple iterations of the geometry optimization process are necessary before a final set of structures is obtained. In NMR, the completion of the assignments and Fig. (2) . Heteronuclear NMR depends on the existence of modestly large one-bond, two-bond and 3-bond couplings between 1 H, 13 C and 15 N nuclei. Shown in A) is the magnitude of couplings typically seen in a dipeptide unit. In B) the magnetization transfer route and the types of nuclei that can be detected from a HNCA experiment are shown. In part C) the magnetization transfer route and the types of nuclei that can be detected from a HNCO experiment are shown. Finally, in part D) the magnetization transfer route and the types of nuclei that can be detected from an HNCACB experiment are shown. Fig. (3) . This summarizes the 3D structure determination process. Experimental parameters are fed into a computer and run through a variety of minimization or optimization programs to generate an ensemble of structures that satisfy the experimental constraints. Shown on the arrow below is the typical amount of time required to perform each task using manual or more conventional approaches. Recent advances are shortening these steps by a factor of 100 or more. the determination of the structure is often regarded as only the first step in analyzing a protein. From this point it is possible to investigate ligand interactions, protein-protein interactions, protein dynamics, catalytic mechanisms, binding mechanisms and a host of other interesting molecular phenomena [26, [41] [42] [43] .
The methods and processes described here provide only a generic "snapshot" of the structure determination process. Advances in NMR methodology, especially in protein NMR, are continually being made and these are substantially changing the process and opening the door to new opportunities. What follows is a more detailed description of recent developments or innovations that are changing the way protein NMR is done.
INNOVATIONS IN SAMPLE PREPARATION
The biggest bottleneck to protein structure determination, whether by NMR or X-ray crystallography, is sample preparation. Sample preparation is simply the process of preparing a sufficient quantity of pure, well-behaved, soluble protein to begin structural studies. This aspect of the structure determination process can sometimes take years of painstaking trial and error. No single method seems to work for all proteins. Fortunately, due the efforts of many recent structural genomics projects and the continuing innovations emerging from the biotech industry, a number of improvements in sample preparation techniques have been made [4, 23] . These innovations are making the sample preparation process somewhat faster and substantially easier.
In NMR spectroscopy, one generally tries to obtain a protein sample that is pure (>95%), mostly folded, monomeric (or at worst, dimeric), soluble for extended periods of time (days), stable to concentrations of ~1 mM, and appropriately labeled with 13 C, 15 N and/or 2 H isotopes. The requirements for both quantity (10's of mg) and isotopic labeling usually mean that protein samples prepared from NMR must be cloned into high expression microbial hosts. ) that allow a range of proteins to be expressed inside the cell without fear of proteolytic degradation. There are also a number of E. coli strains that have been specifically developed to permit residue-specific isotopic labeling [44, 45] . These auxotrophic bacteria have had certain key genes in amino acid synthetic pathways knocked out, so they require specific amino acid supplements in their growth media. Residue-specific labeling is a very powerful approach to assigning or analyzing very large proteins by NMR as it greatly simplifies their spectra and allows individual amino acid types to be unambiguously identified [45, 46] .
The use of Pichia pastoris, a methylotrophic yeast, has been shown to yield very high quantities (100's of mg/L) of larger proteins that cannot be expressed in bacteria [47, 48] . The more sophisticated folding apparatus, better redox control (for disulfide bonded proteins) and better protein export found in Pichia allow isotopically labeled proteins to be isolated quite simply from the growth media. More recently, mammalian and baculovirus systems have been developed for expressing labeled proteins for NMR [49, 50] . These eukaryotic systems require a fairly sophisticated and expensive growth medium, but for proteins that cannot be expressed any other way, these eukaryotic systems are sometimes the only option.
To facilitate the search for an appropriate host (different strains of bacteria, yeast, baculovirus, etc.) the development of ligation independent cloning methods (LIC) such as Invitrogen's Gateway system has made the process much easier and much faster. LIC allows the simultaneous and facile preparation of expression vectors for a variety of different hosts, with a variety of different affinity tags [51] . All too frequently, structural biologists make the mistake of working with only a single host to investigate expression optimization. The more successful structural biology labs routinely try half a dozen or more hosts along with several different types of expression vectors containing different affinity or solubility tags. A major innovation in protein expression and purification has been the near-universal adoption of affinity and/or solubility tags [52] . Prior to the appearance of protein or peptide fusion tags, most protein purification protocols had to be worked out and optimized individually. This frequently led to long, tedious, multi-step protocols with very low yields. With affinity tags, purification is often just a single step and yields can approach 90%. The most popular affinity tag is the polyhistidine or His 6 tag, which may be attached either to the N or C terminus of the protein of interest. His 6 tagged proteins can be purified quickly and easily using a nickel-EGTA column [53] . Usually a cleavable linker is introduced between the protein sequence and the His 6 tag, although cleavage is usually not necessary for NMR studies. Other peptide affinity tags can be used such as glutathione transferase (GST), maltose binding protein (MBP) and cellulose binding protein (CBP), although because of their size these tags generally must be cleaved prior to conducting NMR studies. Occasionally the choice (or location) of an affinity tag can substantially affect the yields, function or stability of the expressed protein. Therefore it is always a good idea to try a few different tags or tag orientations [52, 53] . In addition to these affinity purification tags, structural biologists are also investigating the use of solubility enhancement tags or SET's. SET tags are designed to improve protein solubility for poorly behaved proteinswhich is very important for NMR. For instance, poly-lysine tails or an N-terminally fused protein G (B1 domain) have been used to good effect [54] .
Proteins need not be expressed in living hosts. Recently, the use of in vitro or cell-free protein synthesis systems has been show to be very effective in producing large quantities of pure, easily purified and fully labeled proteins [23, 55] . These systems are based on using either E. coli or wheat embryo transcription/translation machinery that has been isolated and placed into specially designed microtitre plates [55, 56] . The ribosomes, tRNAs and RNA polymerases are then provided with the gene of interest along with an appropriate supply of nucletotide triphosphates, amino acids and other trace elements. Sometimes chaperonins, disulfide isomerases and other protein folding facilitators may be added to the mixture. Yields from these in vitro systems can approach an astonishing 6 mg/mL [23] . Residue specific and uniform isotopic labeling is easily attainable with cell-free systems [57] . In vitro or cell-free systems are very costeffective (high yield per unit of labeled amino acid) and require minimal sample handling. However, they do not work for all proteins.
In addition to better expression and purification systems, NMR spectroscopists have also come up with much better isotopic labeling methods. By exploiting our extensive understanding of amino acid metabolism, a variety of schemes have been developed to allow selective labeling of amino acids or parts of amino acids (i.e. methyl groups) with either 13 C or 2 H isotopes [46, 58] . By eliminating large numbers of signals and reducing dipolar broadening effects, these selective labeling schemes have allowed very large proteins to be assigned and solved by NMR [27, 59] . They have also allowed very detailed dynamic studies to be performed. Likewise the development of more sophisticated (richer) media, the use of mild heat-shock or better timing in the introduction of labeled isotopes into the growth media has greatly improved protein yields or substantially cut labeling costs [60, 61] .
Another innovation in isotopic labeling is the concept of segmental labeling through trans-splicing or intein-based chemical ligation [62] . Segmental labeling allows different protein segments or domains to be labeled, thereby greatly simplifying the NMR spectra of larger proteins. Inteins are the protein equivalents of introns. They are insertional sequences in proteins that splice themselves out after translation. During the splicing process, the intein is removed and the protein fragments preceding and following the intein are joined [63] . By preparing an isotopically labeled domain with an intein sequence at the C-terminus and adding a second, unlabeled domain with a cysteine at the N terminus, the splicing reaction can be initiated leading to a hybrid or chimeric protein with one part of the protein labeled and the other part not [62, 64] .
Even after a protein has been purified, appropriately labeled and placed in an NMR tube, many challenges still exist. Frequently, under seemingly benign conditions, proteins will precipitate or form large multimers after a short period of time. This obviously prevents good quality NMR spectra from being collected. Usually NMR spectroscopists must spend a good deal of time finding optimal solution conditions for their protein to collect the necessary spectra. This is called sample conditioning [65] . It is not unlike the sampling process that X-ray crystallographers use to find crystals. In sample conditioning one tries to sample a large number of pH, temperature and salt conditions to find the optimal solution conditions for collecting NMR spectra [66] . The so-called button test [67] has been developed to facilitate this process. The button test uses a microtitre plate and dialysis film to allow large numbers of sample conditions to be evaluated and for precipitation events to be detected, using a minimal amount of protein. In addition to changing pH or salt conditions, occasionally the addition of other cosolvents (trifluoroethanol, dimethylsulfoxide) or detergents can help [68, 69] . Recently, the use of inverted micelles in low viscosity solvents has been shown to yield some promising results in tackling difficult proteins [70] . Likewise, limited proteolytic digestion of loose, hydrophobic tails can sometimes lead to a more stable protein that behaves much better in the NMR tube [65, 71] .
INNOVATIONS IN INSTRUMENTATION AND DATA COLLECTION
Advances in instrumentation and pulse sequence design are probably the main reason why NMR spectroscopy has grown so spectacularly over the last decade. Obviously, improvements in computer speed and data storage capacity have greatly helped in all areas of spectroscopy (and science). However, other kinds of instrumental innovations are probably having more of an impact in NMR. Ultra high field (900 MHz) instruments are one such example [19, 21] . In NMR, higher magnetic fields yield better resolution as the chemical shift dispersion increases linearly with field strength while the line widths basically stay the same. Better resolution means that larger proteins can be studied and that more spectral detail can be collected on smaller proteins. Likewise stronger magnets lead to better signal-to-noise, increasing roughly as the 7/4 power of the magnetic field. Therefore, better spectra can be collected in less time or with less material. Increased field strength also allows certain phenomena related to chemical shift anisotropy (CSA) and dipolar coupling to be exploited, leading to a new-found ability to collect spectra with very narrow lines (the TROSY experiment).
In addition to increased field strength, more and more NMR magnets are being made with active shielding. Active shielding reduces the stray field (the five gauss line) outside the magnet, thereby allowing NMR instruments to be housed in smaller rooms. Active shielding also allows other instruments (mass spectrometers (MS), liquid chromatography equipment (LC), robotic sample changers) to be brought into closer proximity. By allowing this kind of instrumentation closer to the NMR magnet, new kinds of hybrid NMR techniques are being developed, including LC-NMR and LC-MS-NMR [72] . These hybrid methods allow NMR spectroscopists (and medicinal chemists) to characterize ligand binding events or to screen compound libraries against new protein samples using the combined strengths of NMR, mass spectrometry and liquid chromatography. By coupling these NMR system to flow-probes, which eliminates the need for glass NMR tubes, NMR data collection can become much faster and far more automated [21] .
Cryogenically cooled probes (probes which have had their electronics cooled to near absolute zero via liquid helium) are another important instrumental innovation that is now becoming commonplace in protein NMR. By supercooling the probe electronics, thermal noise is almost eliminated and the signal-to-noise can be increased by a factor of three or more [20] . This innovation has made it possible to inexpensively convert a lower field instrument (say 500 MHz) to the equivalent of a higher field (say 800 MHz) instrumentat least in terms of sensitivity. Other probe design innovations are allowing much smaller sample volumes to be used, greater tolerance of salt and greater limits in allowable temperatures or pressures [21] .
Spurred on by these new instrumental advances, NMR spectroscopists have been able to measure or design pulse sequences that allow them to measure new kinds of NMR parameters. Relative to other kinds of spectroscopy, NMR is particularly rich in spectroscopic observables. Chemical shifts, spin couplings, dipolar couplings, relaxation times, nuclear Overhauser effects cross-correlated relaxation rates, chemical exchange rates, chemical shift anisotropy (CSA), and so on can all be measured (either alone or in combination) for a variety of nuclei under a variety of conditions. Each of these observables, if appropriately measured and analyzed, can provide quantitative structural or dynamic information.
Among the most exciting "new" parameters to emerge in protein NMR have been residual dipolar couplings or RDC's [24, 73] . These are different from spin-spin or J couplings in that the peak splitting arises when two nearby nuclear dipoles are differentially oriented relative to the external magnetic field. In solution, these dipolar couplings are normally averaged to zero, so we just observe J-couplings. In solids, these dipolar couplings are very large and actually dominate the spectrum. If solution conditions can be found that give proteins a partial or residual orientation these dipolar couplings, which are relatively small (-20 to +20 Hz) can be observed. By making use of dilute solutions of bicelles [20] , filamentous phage particles [74] or other large polymers which weakly bind proteins, NMR spectroscopists have found that proteins can be weakly oriented to yield measurable residual dipolar couplings. Because these couplings depend on the orientation of the protein relative to the external magnetic field as well as the orientation of the dipole pair within the protein, RDCs can be used to extract so-called "long range" information. In other words, RDC's can provide information about the orientation of two helices relative to one another or even about the orientation of two domains relative to one another [75] . The use of RDC's has become increasingly prevalent in protein structure determination and refinement as these longer range constraints greatly improve the quality and precision of protein structures [73] . More recently, protein structures have actually been generated using only RDC data [76] , which opens up the exciting possibility of doing NMR without NOE's.
Residual dipolar couplings are not the only types of couplings to have been "discovered". Other types of spin couplings have recently been observed which allow even more geometrical or constraint information to be derived. These include the measurement of internuclear 3 J NC' couplings arising between hydrogen bonds [77] , the measurement of 3 J Hα-1N couplings, via HN(CO)CA experiments, which provide information on protein ψ angles [78] and the measurement of 3 J C'Hα couplings, via HCANC' experiments, which provide information on backbone φ angles [79] . Many other J-coupling constants, which provide side chain χ 1 angle information, are also measurable using modified 2D and 3D heteronuclear experiments [80] . In addition to these new coupling constant measurements, the measurement of crosscorrelated relaxation (the differential relaxation rates arising from two sets of dipoles having different orientations) has been found to provide very precise determination of backbone torsion angles [81] . Similarly the measurement of carbonyl carbon CSA-mediated cross-correlated relaxation in the smaller, uniformly labeled proteins has been found to yield remarkably accurate values for backbone ψ angles [82, 83] .
It is important to remember that the measurement of new NMR parameters requires the development and implementation of new pulse sequences. These pulse sequences allow the magnetization in a protein system to be moved around and for the various coupling/relaxation phenomena to evolve and transfer to other nuclei. Innovations in pulse sequences allow different combinations of chemical shifts, couplings and relaxation times to be displayed, selected or detectedeither along different axes or with different intensities. For instance, the development of pulse sequences to enable 3D and 4D NMR has allowed far more spectral information to be displayed and correlated in a single spectrum [16, 17] , the invention of the HNHA pulse sequence has allowed far more accurate 3 J HNHα coupling constants to be measured [80] , the development of MUSIC pulse sequences has allowed individual amino acid types to be identified -without the need for residue-specific labeling [84] , while the use of pulsed-field gradients has improved the sensitivity of many NMR experiments by a factor of two or more [85] .
One particularly important pulse sequence innovation is known as transverse relaxation optimized spectroscopy or TROSY [86] . This pulse sequence exploits the differential relaxation effects arising from chemical shift anisotropy (CSA) and dipole-dipole (DD) coupling. At higher magnetic fields (>500 MHz), these differences are quite noticeable. If these two (CSA/DD) interactions are measured on an uncoupled 15 N HSQC spectrum, four differently-shaped peaks are seen. To simplify their spectra and increase signal intensity, NMR spectroscopists normally decouple their HSQC spectra yielding a single broad peak. However, if the pulse sequence is modified so that only the narrowest peak is selected, then the resulting NMR spectrum is much better resolved (by a factor of two or more). While some signal intensity is lost, the improvement in resolution more than makes up for this deficit. Indeed, TROSY spectroscopy has become widely adopted by many protein NMR labs because the improvements in resolution can be quite spectacular. The difference between dipole-dipole coupling and CSA relaxation is predicted to maximize near field strengths of 1000 MHz [59] . Hence the TROSY phenomenon is putting greater pressure on magnet manufacturers and NMR spectroscopists to build (and buy) higher field instruments. The TROSY pulse sequence can be inserted into most standard 2D and 3D NMR experiments, meaning that TROSY experiments can be performed and the benefits can be realized quite easily.
More recently, NMR "spin jockeys" have turned their attention to finding ways of not only improving resolution and sensitivity, but to accelerating data collection. A single 3D or 4D NMR experiment can take as long as five to six days to collect. Given that as many as six or seven 3D experiments may have to be collected to fully assign a protein, this represents an enormous amount of time devoted to data collection. Indeed, it was reaching a point where data collection was taking longer than the assignment and structure determination process. The development of projection reconstruction [87] , GFT-NMR [88] and Hadamard spectroscopy [87] along with other data processing approaches such as filter diagonalization [89] has potentially shortened the data collection period by a factor 10 or more. Now it is possible to collect many kinds of 3D and 4D spectra in less than a few hours. Other approaches aimed at combining several kinds of 3D spectra together, will likely reduce data collection time even further [90] .
INNOVATIONS IN SPECTRAL ASSIGNMENT AND VALIDATION
Spectral assignment or sequential assignment refers to the process of assigning of atoms to individual NMR resonances or chemical shifts. This is perhaps the most manually intensive and error-prone step in protein NMR. The fact that there is no simple mathematical transformation that converts experimental data to structure (as there is with X-ray crystallography) has always been something of an Achilles heel to protein NMR. Consequently there have been a number of efforts aimed at either doing away with this step entirely [91, 92] or completely automating the NMR assignment process [93] .
Since the early 1990's several reports have been published which demonstrated the possibility skipping the assignment process and going straight from raw spectral data to a solved 3D structure. The first effort was described by Per Kraulis [94] who demonstrated the feasibility of generating 3D structures of two small proteins (BPTI and GAL4) using 13 C/ 15 N separated heteronuclear NOESY data. Of course from the solved structure it was a simple matter of automatically extracting the assignments. More recently, Grishaev and Llinas [92] have used a slightly different approach to generate 3D structures of two small proteins (~70 residues) using only homonuclear NOESY data. The basic concept involves using molecular dynamics and simulated annealing to condense a "gas" of unassigned, unconnected H atoms into a structured proton distribution (cloud) using only internuclear distances (from NOE intensities) and van der Waals repulsive terms as restraints. The protein sequence is then mapped to the cloud of protons to generate a complete, connected polypeptide structure. Once again, no assignments are necessary, however the algorithm is very computationally intensive and requires days or weeks of CPU time. More recently Atkinson and Saudek [91] have demonstrated that the 3D structure of ubiquitin can be generated independent any prior spectral assignments. The process is based on using a large number of 3D heteronuclear experiments and a single 4D heteronuclear NOESY experiment. Each peak (or coupling constant) serves as a very crude distance constraint between pairs of atoms. For instance, the appearance of 75 NH cross peaks in a 15 N HSQC spectrum provides a constraint indicating that 75 NH atom pairs exist within a pairwise distance of 1.0 -1.1 Å. By measuring enough experimental data and providing a sufficient number of constraints, a reasonably good structure can be generated (from which the assignments can be readily inferred). The method appears to be limited to relatively small proteins which have had a very large number (>10) of high quality 3D heteronuclear spectra collected and analyzed.
The other approach to protein assignment is to let the computer do the job or at least assist with the job. There are a large number of automated and semi-automated approaches that have been published or described including AUTOASSIGN [95] , GARANT [96] , Smartnotebook [97] , PASTA [98] , CAMRA [99] and others [93] . Some are restricted to using homonuclear 1 H spectra and so are critically dependent of having very good quality TOCSY and NOESY data. Others are more general or use heteronuclear 2D and 3D experimental data. These approaches do not require NOESY data, but do require a standard set of six to nine high quality spectra to complete the assignment process.
All automated or semi-automated methods are limited by the NMR spectroscopist's axiom: "Garbage in = Garbage out". In other words, if the spectra are of poor quality and have poor signal to noise, all methods will do poorly. On the other hand, if the spectra are largely noise-free, almost all the automated and semi-automated methods will do very well [93] . Under ideal circumstances it is possible to go from a set of appropriately processed spectra to a complete set of assignments in as little as 10 seconds. Automated assignment strategies typically proceed through five steps including: 1) peak picking and referencing; 2) spectral or spin grouping; 3) spin system identification; 4) sequential spin linking and 5) mapping the linked spins to the protein sequence. The weakest link in fully automated assignment methods is invariably the peak picking step. Computers are not very good at distinguishing noise from real spectral data. This is why semi-automated methods which typically require human-aided peak selection usually perform best. Another major problem both in automated and manual assignment methods is the chemical shift "drift" which occurs between experiments. This makes spectrum to spectrum comparison and peak-to-peak registration difficult and sometimes very confounding [93] .
The assignment process (whether automated or manual) can be greatly aided if one has some prior knowledge about what the chemical shifts might be. In this regard, several approaches have been developed which allow researchers to use either sequence homology (to previously assigned proteins) or known coordinates (of identical or homologous Xray structures) to predict chemical shifts. These methods are quite accurate and, if the sequence identity is high enough (>35%), greatly improve the performance of any assignment strategy.
Once a protein has been assigned, there are relatively few "independent" ways of determining if any given chemical shift assignment is correct. The establishment of the BioMagResBank (BMRB) has allowed NMR researchers to determine average chemical shifts as well as typical chemical shift ranges for 1 H, 13 C and 15 N nuclei for all amino acid residues [102] . Tables of these nucleus-specific averages and their associated standard deviations have been published [7, 103, 104] and are also available at the BMRB website. These average values, standard deviations and expected ranges can be used to ascertain the correctness of assigned chemical shifts in proteins. For instance, an alanine residue with a 13 Cβ shift of 44.7 ppm would be quickly flagged as in "impossible" shift because the normal range for alanine 13 Cβ shifts is 18.7 +/-8.5 ppm (where 8.5 ppm is five standard deviations).
More sophisticated approaches for chemical shift assignment validation are also available. One approach, which can be used after the structure has been solved (or if an existing X-ray structure is known), is called SHIFTCOR [104] . This web-based server for protein chemical shift validation allows users to compare the observed chemical shifts to those predicted from the corresponding 3D structure via a chemical shift prediction program called SHIFTX [103] . SHIFTCOR is particularly good at finding chemical shift referencing problems (which are embarrassingly frequent) and catching inadvertent assignment switches (e.g. serine/threonine misassignments). Stand-alone programs such as SHIFTS [105] and TOTAL [106] may also be used to validate assignments through similar back-calculation schemes.
INNOVATIONS IN 3D STRUCTURE GENERATION AND VALIDATION
Structure generation in NMR is an inherently computerintensive process. However, most of the data needed for structure generation still has to be entered and validated manually. Consequently, most of the recent innovations in NMR structure generation have focused on reducing this emphasis on manual data entry [4, 25] . Additionally, a number of new spectral parameters have emerged (RDC's, new kinds of J-couplings, paramagnetic relaxation data) and a number of key spectral parameters have been proven to be more precisely calculable (NOE's and chemical shifts). The inclusion of these novel constraints, along with empirical database potentials [107] , has also been a major focus in protein structure generation over the past five years. This is because many of these new constraints can significantly improve the quality of NMR-generated protein structures [73] . Using these new constraints in structure generation, at least from the perspective of a user, is relatively painless. This is because nearly all NMR-based protein structure generation programs depend on a molecular dynamics or energy minimization "engine" such as CNS/XPLOR [40] , AMBER [108] , CHARMM [109] or DYANA [110] with an extensive set of empirically derived bond lengths and bond potentials. These programs are being continually updated by teams of programmers to accommodate the latest set of measurable NMR parameters, so it is important for users to stay current with the latest releases.
Because protein structure generation by NMR is still largely dependent on NOE data, improvements in NOE analysis has been a major focus. For a long time it has been recognized that one of the major bottlenecks in protein structure determination is the assignment of NOE's. In many cases there are ambiguous NOE's that arise from protons having the same or nearly identical chemical shift. For larger proteins, it turns out that most NOESY cross peaks are ambiguous. A program called ARIA (Ambiguous Restraints for Iterative Assignment) has recently been developed which deals with ambiguous NOE's and automatically generates protein structures using only a chemical shift assignment list and a list of un-assigned or partially assigned NOE cross peaks [111] . ARIA uses an iterative, self-correcting approach to deal with wrong NOE assignments or overlapping NOE's. The success of ARIA has led to the development of other NOE-based automated structure generation programs such as ATNOS [112] and NOAH [113] . Given suitably good quality spectra (or peak lists), these methods can automatically generate good quality 3D structures in as little as 10 minutes.
In addition to the assignment-independent methods for structure generation (discussed earlier), there is a growing trend to accelerate the structure generation process by integrating NMR data into powerful structure prediction or fold recognition methods. This integration is leading to 3D structure generation methods that use little or no NOE information. Several groups have employed the idea of using chemical shifts, which provide residue-specific secondary structure information [114] , as experimental constraints for protein threading algorithms [115, 116] . Protein threading is a protein structure prediction technique that relies on testing whether a new protein sequence (and any measurable parameters associated with that sequence) is compatible with an existing PDB structure [117] . The inclusion of experimental data appears to improve the reliability of the threading alignment and hence the identification of the protein fold. More recently, the concept of chemical shift threading has been extended to the point where chemical shifts are iteratively calculated and used directly in the threading potential. A new program, called THRIFTY [7] , which uses chemical shift threading appears to be capable of generating high quality 3D structures without any NOE information.
The concept of threading has also migrated into the realm of RDC's. RDC's provide orientational information about bond vectors, but not distance information. The challenge to generating a protein structure from a collection of RDC's is to find a way to orient these vectors (or bonds) in such a way that it agrees with both the experimental measurements and the steric limitations of protein structures. One way of reducing this near-infinite search space it to use existing protein structures or substructures, either through threading [118] or through ab inito folding methods [76] .
Recent assessments of protein structures generated by NMR have pointed to a number of problems with their quality, stereochemistry or assumed resolution -particularly for earlier structures [10] . This has led to the development of a number of software packages that perform detailed structural assessment and validation of protein NMR structures. These packages include, PROCHECK-NMR [119] , VADAR [120] , and WHAT IF [121] . Typically they take PDB files and check atom labels, measure bond lengths and angles, identify and assess hydrogen bonds, identify secondary structure, extract torsion angles, calculate accessible surface area, measured atom contacts, determine residue volume and compare these results to "standard" or idealized values. Residues or atoms that exceed statistically determined thresholds are flagged and the user is asked to check the geometry, labeling or stereochemistry of the suspect atoms.
In addition to these generic structure validation tools, several NMR-specific software packages including DYANA [110] , CNS [40] , AQUA [119] , and SHIFTCOR [104] offer a rich collection of diagnostic tools to check for violations or variations between experimental NMR data and calculated coordinate data. By compiling data on a number of wellresolved, fully assigned and carefully refined NMR structures it has been possible to get some useful estimates or thresholds which are indicative of higher quality structures [122, 123] . In general, "good" NMR structure(s) should have 1) no persistent NOE violations greater than 0.5 Å; 2) a standard deviation of less than 0.05 Å for all NOE violations; 3) an NOE completeness of at least 50% for all observable protons within 4 Å of each other; 4) an RMSD of < 0.5 Å for backbone atoms (calculated over >20 structures); 5) and RMSD of < 0.8 Å for all atoms (calculated over >20 structures); 6) acceptable torsion angles (>90% in the allowed regions); and 7) fewer than 1% of all chemical shifts that are outside of predicted or generally accepted ranges (within 3-4 standard deviations). Regardless of how one chooses to validate an NMR-generated structure, validation is a necessary step in the structure generation process -it should not be avoided.
NMR OF PHARMACEUTICALLY IMPORTANT PROTEINS
It is important to remember that proteins can serve as both drugs and drug targets. Obviously those in the biopharmaceutical industry tend to view many proteins as probable or potential drugs. Indeed, the FDA has already approved of more than 100 protein and peptide drugs including a variety of growth factors, hormones, antibodies and chemokines. Hundreds more are expected to be approved in the next decade. On the other hand, those in more traditional pharmaceutical disciplines tend to view proteins primarily as targets for small molecules. Indeed, of the thousands of small molecule drugs approved by the FDA, more than 95% of them target specific proteins or peptides. Regardless of whether a protein is being studied as a drug or as a drug target, knowing something about its structure can help us understand its mode of action (if it is to be a drug) or how it could be activated/deactivated (if it is to be a drug target).
NMR can play a role in both areas of protein-based drug discovery. Not only does NMR reveal important structural information, but it allows scientists to probe the dynamics, interactions and binding events that are vital to understanding drug action or discovering new, small molecule drug leads. Because of its versatility, NMR has found a number of useful niches in structure-aided drug discovery and development, particularly in areas where X-ray crystallography has proven inadequate. These include the characterization of: 1) smaller, flexible hormones or peptides; 2) smaller, more disordered or more flexible proteins; 3) protein domains or modules; and 4) protein-ligand interactions [4, 42] To get a better idea of NMR's growing role in drug discovery and development, a partial list of pharmaceutically important peptides and proteins that have been solved by NMR is provided in Table 1 . This list includes the protein/ peptide name, the PDB coordinates (X-ray or NMR, whichever is more recent) and the BioMagResBank accession number. It is important to point out that this table lists only the publicly deposited coordinates and NMR shifts and it does not include dozens of other proteins that are being studied by the pharmaceutical industry. Likewise, due to space limitations, not all proteins of biomedical interest can be included here.
Inspection of this table reveals that there are five general classes of proteins where NMR has been most frequently used. These include the chemokines (interleukins and interferons), growth factors or hormones (TGF, EGF, BFGF, HGH), antimicrobial peptides (hepcidins, bacteriocins, tachystatins), immunity proteins (FK506, cyclophilin, defensins) and viral targets (HIV and heptatitis viruses). These reflect the particular strengths of NMR in determining the structures of smaller, more flexible proteins and peptides. With recent advances in NMR technology, larger proteins are being tackled and it is likely that more enzymes (kinases, phosphatases, proteases, metabolic enzymes) will appear in the near future. Indeed, many of the proteins being studied by the pharmaceutical industry today fall into this category. Unfortunately, confidentiality issues prevent information (coordinates, chemical shifts) about these targets from being publicly released.
Structural studies by NMR of many of these chemokines and growth factors have revealed that their active sites or binding loops tend to be quite flexible, with relatively little defined structure [124, 125] . This is in contrast to the rigid, well-defined structure that is often implied through X-ray crystallography of the same or similar proteins. Interestingly, the rigid structures observed via X-ray now appear to be artifacts, largely due to crystal packing effects. In this regard, NMR has revealed a key insight into chemokine/growth factor function and activity that could not have been obtained via crystallography. Evidently, this active-site flexibility appears to be vital to facilitating or accommodating proteinprotein or protein-receptor interactions [124] [125] [126] . Indeed, it is often possible to identify the active sites of proteins via NMR by simply looking for missing or poorly resolved peaks among sequentially or spatially proximal residues.
Studies of the active site structure of growth factors and chemokines have also led to the development of peptide/ protein analogs and a number of potentially interesting small-molecule or minimal peptide drug leads [126] [127] [128] . In this regard, the structural characterization of prospective protein drugs is motivating the development of prospective small-molecule drug analogs.
Of course not all proteins and peptides are potential drug candidates. Indeed the vast majority of proteins being studied by the pharmaceutical industry are actually drug targets -not drug leads. Because the objective is to develop a small molecule that binds to the protein, the protein structure (and NMR assignments) is not an end in itself, but a means to an end. In other words, protein-ligand interactions are what much of drug discovery is about.
NMR IN DRUG DISCOVERY -MONITORING LIGAND INTERACTIONS
No other form of spectroscopy and certainly no variant of X-ray crystallography can match NMR's intrinsic ability to monitor and detect protein-ligand interactions. NMR is exquisitely sensitive, universally applicable, quantitative, amenable to analyzing complex mixtures and, as we've seen already, able to provide atomic resolution details of ligandprotein binding [42, 129] . Because of the enormous range of concentrations at which NMR signals can be detected and reliably measured (10 -2 M to 10 -6 M), NMR is able to detect the weakest protein-ligand interactions of any method so far identified (i.e. millimolar binding constants). Furthermore, because NMR detects a universally abundant compound (protons), it is possible to design NMR-based screening protocols without any prior knowledge of a protein's function, substrates or substrate analogs. In other words, NMR eliminates the needs to develop bioassays that need specially designed fluorophores, chromophores or substrate analogs. In addition to its near-universality, NMR offers superb approaches to quantifying ligand binding. The ability to resolve individual resonances during an NMR titration allows the precise determination of binding constants, off rates, on rates, allosteric interactions and many other kinetically (and thermodynamically) important parameters. Furthermore, the level of spectral resolution offered by NMR means that dozens of compounds can be monitored simultaneously during any screening or titration processes. This obviously facilitates high throughput screening of ligand libraries. In contrast, the low spectral resolution afforded by UV, IR or fluorescence based methods means that only one (or at most two) compounds can be simultaneously analyzed during binding assays. Finally, outside of X-ray crystallography, NMR is the only spectroscopic method that can provide precise 3D structural details about how and where a ligand binds to a protein.
Over the past ten years NMR researchers, both inside and outside the pharmaceutical industry, have focused a great deal of effort on refining the technology to detect and deconvolve protein-ligand interactions. Essentially two basic approaches have emerged [129] . One is based on using NMR to observe changes to the small molecule ligand (or ligands) when it binds to the protein. This is called ligand-observed screening. The other approach is based on using NMR to observe changes to the target protein when it binds a ligand (or ligands). This is called target or protein-observed screening. These two approaches have emerged to facilitate the discovery of lead compounds, to map the bind sites of lead compounds and to facilitate the rational design of better drug leads.
Ligand-Observed Screening
In ligand-observed screening, it is not necessary to have previously assigned the protein target, nor is it necessary to have a protein that is particularly amenable (small, soluble, stable) to NMR studies. This is because the resonances that are detected or measured are those of the ligand -not the protein. In ligand-observed screening one relies on detecting NMR phenomena that are exacerbated by the size differences between the large protein target and the small molecule ligand (Fig. 5) . Typically, for ligand-based studies to work the dissociation constant (K D ) should be between 10 -7 and 10 -3 M and the mass difference between the target protein and prospective ligand should be greater than 50 fold. If these conditions are met a variety of specially designed pulse sequences it is possible to "filter" or select for the resonances of ligands that exhibit different affinities. In this way it is possible to work with mixtures of ligands, yet only see the ligand of interest in the resulting NMR spectrum [129, 130] .
When small ligands transiently bind to a protein three things happen. Their diffusion rate slows, their line widths broaden (fast relaxation) and their NOE's shift from positive to negative (Fig. 5) . A number of elegant approaches have been developed over the past five years which exploit the measurement of decreased diffusion coefficients via NMR. Techniques such as DOSY (diffusion ordered spectroscopy - [130] ), diffusion modulated gradient COSY [131] or diffusion-encoded TOCSY [132] experiments have been developd which allow molecules (and spins) to be separated by their diffusion coefficients. Alternately, changes in linewidth (or T 2 ) or other magnetic relaxation rates (T 1 or T 1ρ ) among ligand resonances can also be used to detect transient binding [129] . In these experiments the diffusion filter is replaced with a relaxation (spin-echo or CPMG) filter. These relaxation methods typically depend on subtracting "before and after" spectra where the spectrum of ligand alone is collected first and then a spectrum collected with the protein added to the ligand. Both T 1 and T 2 (line width) based screening methods have been proposed and shown to work reasonably well [129] .
Another route to measuring ligand interactions is to exploit the changes in intramolecular magnetization transfer or transferred NOE's [133] . Transferred NOE's (trNOE) require somewhat special conditions where binding constants are weak and off-rates are sufficiently fast. If these condi-tions are met it is possible to detect the transient NOE's that develop between the protein target and the ligand. In particular, the resonances from the free ligand will exhibit an intense negative trNOE as a "memory" from when it was bound to the protein. The appearance and intensity of these negative NOE's can be used to detect and measure protein ligand interactions. In addition to measuring intramolecular NOE's, it is also possible to measure intermolecular NOE's. In these experiments the magnetization is transferred from the protein (via frequency selective irradiation on the methyl groups around 1 ppm) to the ligand. A second reference spectrum (without irradiation) must be subtracted from the first spectrum to identify the relevant intensity changes in the ligand resonances. Saturation transfer difference (STD) spectroscopy is the term normally applied to this kind of experiment [134] . It can be coupled to other kinds of 2D experiments (TOCSY or HMQC) to alleviate spectral overlap problems. The resulting spectra typically show distancedependent signal intensity changes in the ligand resonances, with the greatest differences corresponding to those ligand nuclei that are closest to the protein. NOE pumping [135] and WaterLOGSY [136] experiments are variants of STD which also have been shown to work well. In WaterLOGSY the magnetization from protein-bound water molecules is transferred to the ligand instead of magnetization from the protein itself.
The main limitation to ligand-observed screening is that fact that relatively little structural information can be obtained regarding how or where the ligand is interacting with the protein. While some information about the ligand structure (or structural changes) is obtainable, the primary role for ligand-observed screening is to identify compounds that bind to a given protein target. Ultimately it is the role of target-observed screening to figure out how these compounds bound.
Target-Observed Screening (Mapping)
In target-observed screening (or mapping), one is focused on measuring and mapping the perturbations to the protein target resonances when a ligand binds [129] . Therefore it is essential to have the resonances of the protein of interest fully assigned (and, ideally, a structure determined). Unlike ligand-observed screening methods, there is no limitation on the affinity, binding constant or on/off rates for targetobserved screening. Furthermore, target-observed mapping allows one to obtain detailed information about the orientation and placement of the ligand relative to the protein and how that ligand affects the target protein structure. This kind of information is critical to doing structure-aided drug design. However, the major limitation to target-observed mapping is that one is restricted to working with proteins that are sufficiently small and well-behaved so that their resonances may be fully observed and assigned.
Five major approaches to target-observed mapping exist. They include: 1) mapping via intermolecular NOE's; 2) chemical shift mapping; 3) mapping with dynamics; 4) mapping with amide exchange; and 5) mapping with paramagnetically labeled ligands. NOE mapping is essentially an extension of standard 3D structure determination, except that two molecules are involved (the ligand and the protein) rather than just one. Unlike ligand-observed screening with transferred NOE's, target-observed screening via NOE's requires tight binding (K D < 10 µM). To facilitate studies with larger molecules, many NOE mapping approaches use isotope-edited NOESY techniques [137] . This requires that the target protein be isotopically labeled ( 1 H, 13 N, 15 N) and the ligand unlabeled (or vice versa). Isotope editing allows one to unambiguously discriminate between NOE's within the protein target and between the two molecules. NOEbased approaches are particularly useful if one is trying to generate a detailed 3D structure of a protein-ligand complex or in situations where the ligand binding induces substantial changes to the protein structure (requiring a complete reassignment of the target protein spectrum - [138] ). The NOE's measured through these approaches can be used in standard distance geometry or simulated annealing programs to generate 3D coordinates.
Chemical shift mapping has become the most popular approach to mapping ligand interactions in NMR. This is because it is both quick and easy to do. In essence the ligand of interest is titrated with an isotopically labeled (usually 15 N) verion of the protein of interest. With each addition of the ligand an HSQC (heteronuclear single quantum coherence spectroscopy) spectrum of the protein is collected and the chemical shift changes are recorded. Chemical shift mapping is best used when the perturbations to the protein upon ligand binding are relatively minor (which is generally true). Chemical shifts are extremely sensitive to changes in geometry, local charge effects and hydrogen bonding. Consequently most ligand binding events will lead to measurable protein chemical shift changes where the ligand is binding. Plotting the chemical shift changes through the course of a titration allows one to not only identify where the ligand is binding, but also to determine the affinity, stoichiometry, specificity and even the kinetics of binding [42, 129] . While chemical shift mapping cannot yet provide sufficient detail to generate 3D structures of bound ligands, chemical shift perturbations can be used as constraints in molecular docking programs to generate approximate models showing where and how ligands have bound to their target protein [139] . Chemical shift mapping methods actually form the basis to a technique called SAR-by-NMR (structure activity relationships by NMR) that was developed and patented by Steve Fesik and co-workers [41] . In SAR-by-NMR a series of weak-binding ligands are identified and their binding positions or orientations mapped on the target protein. By chemically linking adjacently mapped ligands it is possible to enhance the binding and develop much higheraffinity ligands.
When a ligand binds to a protein, not only do chemical shifts change, so too do the protein's local motions. Ligand mapping via the measurement of 15 N relaxation rates (i.e. backbone dynamics) has been shown to provide some insight into how and where ligands bind on target proteins [42] . Typically binding appears to quench the motion at the ligand-protein interface, as might be expected. However, dynamic mapping requires the determination of many relaxation rates, the calculation of order parameters and the use of several complex models. In many cases the results are quite ambiguous. More recently the use of dynamic mapping with 2 H, 13 C labeled methyl groups appears to offer a better route to understanding and mapping ligand interactions.
Amide exchange mapping involves measuring amide exchange rates (via HSQC spectra) for amide protons in the protein before and after a ligand has bound [140] . If the binding is sufficiently tight, amide exchange rates will typically slow down in the region where the ligand has bound. However, sometimes ligand binding will lead to a global change in amide exchange rates which can make the interpretation of amide exchange rates difficult. An alternative to amide exchange mapping is paramagnetic mapping [42] . In this case a ligand is either modified to contain a paramagnetic moiety or a non-paramagnetic ligand (metal) is replaced with a paramagnetic metal. Paramagnetic groups will cause either line broadening (relaxation reagent) or chemical shifting (shift reagent) especially for residues proximal to the paramagnetic moiety's binding site. Paramagnetic changes depend on a simple r -6 law and so in some cases it is possible to get very precise distance constraints from these paramagnetic perturbation experiments.
CONCLUSION
Since the first crude protein structure was determined some 20 years, NMR has evolved quickly to become a central pillar in structural biology. No other form of spectroscopy can provide the exquisitely detailed picture of macromolecular structure and dynamics that NMR can offer. However it is important to remember that NMR can be more than just a protein structure elucidation tool. Indeed, determining the structure of a protein by NMR is simply the first step in a process that can ultimately lead to the discovery and development of many pharmaceutically important products or ideas. The potential applications of NMR in nearly all aspects of pharmaceutical biotechnology will likely continue to expand. Given the rapid pace of technological advancement in NMR and the growing trend towards simplifying many of the processes, it is likely that NMR will become much more accessible and useful to a much larger community of pharmaceutical researchers.
